

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant  
treatment of muscle-invasive bladder cancer ID6607**

**Provisional Stakeholder List**

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>MSD (pembrolizumab)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>Action Bladder Cancer UK</li> <li>Black Health Agency for Equality</li> <li>Bladder and Bowel Community</li> <li>Bladder and Bowel UK</li> <li>Cancer 52</li> <li>Cancer Black Care</li> <li>Fight Bladder Cancer</li> <li>Independent Cancer Patients Voice</li> <li>Macmillan Cancer Support</li> <li>Maggie's Centres</li> <li>Marie Curie</li> <li>South Asian Health Foundation</li> <li>Specialised Healthcare Alliance</li> <li>Tenovus Cancer Care</li> </ul> <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> <li>Association of Cancer Physicians</li> <li>British Association of Urological Nurses</li> <li>British Association of Urological Surgeons</li> <li>British Geriatrics Society</li> <li>British Institute of Radiology</li> <li>British Oncology Pharmacy Association</li> <li>British Psychosocial Oncology Society</li> <li>British Society of Urogenital Radiology</li> <li>British Society of Urogynaecology</li> <li>British Uro-Oncology Group</li> <li>Cancer Research UK</li> <li>Royal College of General Practitioners</li> <li>Royal College of Nursing</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>All Wales Therapeutics and Toxicology Centre</li> <li>Allied Health Professionals Federation</li> <li>Board of Community Health Councils in Wales</li> <li>British National Formulary</li> <li>Care Quality Commission</li> <li>Department of Health - Northern Ireland</li> <li>Healthcare Improvement Scotland</li> <li>Medicines and Healthcare products Regulatory Agency</li> <li>National Association of Primary Care</li> <li>National Pharmacy Association</li> <li>NHS Confederation</li> <li>NHS Wales Joint Commissioning Committee</li> <li>Scottish Medicines Consortium</li> <li>Welsh Government</li> </ul> <p><u>Other relevant companies</u></p> <ul style="list-style-type: none"> <li>Astellas Pharma (enfortumab vedotin)</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>Amarox (cisplatin)</li> <li>AstraZeneca (durvalumab)</li> <li>Bristol Myers Squibb (nivolumab)</li> <li>Hospira UK (cisplatin, gemcitabine)</li> <li>Ranbaxy (gemcitabine)</li> <li>Sandoz (cisplatin)</li> <li>Synchrony (gemcitabine)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>Cochrane Urology</li> <li>Genomics England</li> <li>Institute of Cancer Research</li> </ul>

Provisional stakeholder list for the evaluation of enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer ID6607

Issue date: January 2026

© National Institute for Health and Care Excellence 2026. All rights reserved. 1 of 3

<b>Provisional Consultees</b>	<b>Provisional Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Oncology Nursing Society</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	<ul style="list-style-type: none"> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health Wales</li> <li>• UK Health Security Agency</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

## **Definitions:**

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations

and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.